Brad Bolzon, PhD Chairman of the Board
Brad brings more than thirteen years of global pharmaceutical industry experience to Versant's biotech investment team and to Flexion's management team. At Versant, he specializes in early-stage biotech investing with emphasis on new company start-ups; he has created three successful companies in partnership with large pharmaceutical firms.
Prior to joining Versant, Brad served as Executive Vice President, Global Head of Business Development, Licensing & Alliances with Roche. Before joining Roche, Brad held a series of management positions at Eli Lilly and Company in regulatory affairs, clinical research and business development.
He currently serves as a board member for Amira Pharmaceuticals, Antipodean Pharmaceuticals, Sentient Pharmaceuticals, Metabolex, Speedel and as Chairman of the Board of Synosia Therapeutics. He is also Chairman of EuroVentures Inc, a wholly-owned start-up incubator within Versant Ventures.
Brad received PhD and MS degrees in Pharmacology from the University of Toronto and conducted his post-doctoral research training at the Ottawa Heart Institute in Ottawa, Canada.